Prometheus Biosciences

Prometheus Biosciences, Inc. engages in operation of a biopharmaceutical company. It focuses on the discovery, development, and commercialization of novel precision therapeutics and companion diagnostics for patients living with unmet needs in gastroenterology and autoimmune diseases. The company was founded by Scott Glenn and Stephan Targan on October 26, 2016 and is headquartered in San Diego, CA .

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Precision IBD is a Biotechnology company and operator of a drug development precision medicine company intended to develop therapeutics for inflammatory bowel diseases.

Merck

Merck & Co Inc (NYSE:MRK) is set to acquire Prometheus Biosciences for $10.8bn in an all-cash deal, as the US drugmaker aims to bolster its pipeline. San Diego-based Prometheus focuses on diseases caused by abnormal immune system activity and is working on a monoclonal antibody treatment for ulcerative colitis, an inflammatory bowel disease.

Merck makes US$11bn swoop for California biotech

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Prometheus Biosciences, Inc. (NASDAQ: RXDX) to Merck for $200.00 per share in cash is fair to Prometheus shareholders. Halper Sadeh encourages Prometheus shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com.

RXDX Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Prometheus Biosciences, Inc. is Fair to Shareholders

RAHWAY, N.J. & SAN DIEGO--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Prometheus Biosciences, Inc. (“Prometheus”) (Nasdaq: RXDX) today announced that the companies have entered into a definitive agreement under which Merck, through a subsidiary, has agreed to acquire Prometheus for $200.00 per share in cash for a total equity value of approximately $10.8 billion.

Merck Strengthens Immunology Pipeline with Acquisition of Prometheus Biosciences, Inc.

Merck & Co. is in late-stage talks to acquire Prometheus Biosciences Inc., according to people familiar with the matter, a move that could give the big drugmaker promising immune disease treatments.

Merck in Late-Stage Talks to Acquire Prometheus Biosciences

SAN DIEGO, March 09, 2023 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc. (Nasdaq: RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutics for the treatment of immune-mediated diseases, today announced that management will present at the Oppenheimer 33rd Annual Healthcare Conference on March 13, 2023 at 10:40 AM ET.

Prometheus Biosciences to Present at the Oppenheimer 33rd Annual Healthcare Conference

Prometheus Biosciences, Inc. (RXDX) delivered earnings and revenue surprises of 1.10% and 6.71%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Prometheus Biosciences, Inc. (RXDX) Reports Q4 Loss, Misses Revenue Estimates

– Reported strong efficacy and favorable safety results for PRA023 in ARTEMIS-UC and APOLLO-CD Phase 2 Studies –

Prometheus Biosciences Reports Fourth Quarter and Full-Year 2022 Financial Results and Highlights Recent Corporate Progress

Prometheus Biosciences has strong growth potential. Minimal competition ensures demand for its products.

Prometheus Biosciences: Strong Growth

- Digital Oral Presentation on APOLLO-CD Phase 2a primary and secondary results to be presented on March 3 r d -

Prometheus Biosciences Announces Two Oral Presentations on PRA023 at the 18th Congress of European Crohn's and Colitis Organisation (ECCO)

SAN DIEGO, Feb. 09, 2023 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc. (Nasdaq: RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutics for the treatment of immune-mediated diseases, today announced that management will conduct a fireside chat at the SVB Securities Global Biopharma Conference on February 14, 2023 at 12:00 PM ET.

Prometheus Biosciences to Present at the SVB Securities Global Biopharma Conference

The mean of analysts' price targets for Prometheus Biosciences, Inc. (RXDX) points to a 33.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Wall Street Analysts Think Prometheus Biosciences, Inc. (RXDX) Could Surge 33.49%: Read This Before Placing a Bet

Affirm

AppLovin Corp

Guardant Health Inc

Immunovant Inc

Maxar Technologies

Madrigal Pharmaceuticals

Vaxcyte

Rogers

Rumble Inc

Mid-cap stocks are proving to be an attractive investment option over the past few years.

5 Best and Worst Performing Mid-Cap Stocks in Q4 2022

Catalyst Pharmaceuticals

iShares Nasdaq Biotechnology ETF

SAGE Therapeutics

SPDR S&P Biotech ETF

In a strong week for the market, biotech dominated. Today we will cover 3 promising stocks in the space.

Biotech's Blockbuster Week: 3 Stocks to Watch

The average of price targets set by Wall Street analysts indicates a potential upside of 26.5% in Prometheus Biosciences, Inc. (RXDX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Wall Street Analysts Believe Prometheus Biosciences, Inc. (RXDX) Could Rally 26.51%: Here's is How to Trade

AMC Entertainment

Global Business Travel Group I

Mirati Therapeutics

Intellia Therapeutics

Mid-cap companies are fast-growing, young companies that are not as volatile as small-cap and not as stable as large-cap companies.

These Were the 5 Best and Worst Performing Mid-Cap Stocks in Dec 2022

SAN DIEGO, Jan. 03, 2023 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc. (Nasdaq: RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the treatment of immune-mediated diseases, today announced that Mark McKenna, Chairman and Chief Executive Officer and Allison Luo, MD, Chief Medical Officer, will present a company overview at the 41st Annual J.P. Morgan Healthcare Conference on Monday, January 9, at 3:45 p.m. PST.

Prometheus Biosciences to Present at the 41st Annual J.P. Morgan Healthcare Conference

Prometheus Biosciences Inc RXDX shares are trading lower by 6.01% to $110.16 going into the close of Friday's session after the company priced a public upsized $500 million offering.

Why Prometheus Biosciences Stock Is Falling - Prometheus Biosciences (NASDAQ:RXDX)

This biotech stock just jumped over 180% in a single day, and investors want to know if there could be more big gains ahead.

Is Prometheus Biosciences a Good Stock to Buy Right Now?

SAN DIEGO, Dec. 08, 2022 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc. (Nasdaq: RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the treatment of immune-mediated diseases, today announced the pricing of an underwritten offering of 4,545,455 shares of its common stock at a price to the public of $110 per share. All of the shares to be sold in the offering are to be sold by Prometheus. The gross proceeds to Prometheus from the offering, before deducting the underwriting discounts and commissions and other offering expenses, are expected to be $500 million. The offering is expected to close on or about December 13, 2022, subject to the satisfaction of customary closing conditions. In addition, Prometheus has granted the underwriters a 30-day option to purchase up to an additional 681,818 shares of common stock.

Prometheus Biosciences, Inc. Announces Pricing of Public Upsized $500 Million Offering of Common Stock

On December 7, Prometheus Biosciences, Inc. announced positive Phase 2 data for PRA023. Prometheus also announced a proposed Public Offering.

Prometheus Biosciences A Buy On Positive Phase 2 Data

The clinical-stage biotech that specializes in IBD therapies announced positive news regarding two trials for its lead therapy.

Why Shares of Prometheus Biosciences Are Soaring This Week

SAN DIEGO, Dec. 07, 2022 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc. (Nasdaq: RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the treatment of immune-mediated diseases, today announced that it intends to offer and sell, subject to market and other conditions, $250 million of shares of its common stock in an underwritten public offering. In addition, Prometheus intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the public offering. All of the shares to be sold in the offering are to be sold by Prometheus. There can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Prometheus Biosciences, Inc. Announces Proposed Public Offering of Common Stock

Esperion Therapeutics

At least two biotech stocks are triggering an options trading frenzy today, with Prometheus Biosciences Inc (NASDAQ:RXDX) and Esperion Therapeutics Inc (NASDAQ:ESPR) moving in opposite directions following their respective drug updates.

2 Biotech Stocks Options Traders Love Today

Prometheus Biosciences Inc shares have rocketed more than 170% on positive results for its therapeutic candidate PRA023 in both its ARTEMIS-UC Phase 2 and APOLLO-CD Phase 2a studies. Prometheus is developing PRA023, a monoclonal antibody against cytokine TL1A, for the treatment of immune-mediated diseases including ulcerative colitis (UC), Crohn's disease (CD), and systemic sclerosis-associated interstitial lung disease.

Prometheus Biosciences soars as new data indicates therapeutic candidate holds promise for bowel disease

The stock price of Prometheus Biosciences (RXDX) surged by over 180% during intraday trading today. This is why.

News for Prometheus Biosciences Stock (RXDX)